Negotiate with time

What can actually slow aging?

From exercise and diet to experimental therapeutics — what the evidence actually says about slowing biological aging, rated by the strength of the science behind it.

Lifestyle

Behavioral changes with the strongest evidence for slowing biological aging. These are the interventions most people can act on today.

Chronic Stress Reduction

PROMISING

Meditation, mindfulness, and structured stress reduction show evidence of slowing biological aging, though effect sizes tend to be modest.

Mechanism

Chronic stress raises cortisol and inflammatory markers, shortens telomeres, and shifts immune cell profiles. Reducing chronic stress may influence DNA methylation at stress-responsive sites, though the causal pathways are still being mapped.

Clock responsiveness

Some intervention studies show reduced epigenetic age with meditation programs. Immune and inflammatory clocks may respond to stress reduction. Telomere maintenance has improved in some randomized trials.

In practice

Regular meditation or mindfulness practice (15–30 minutes daily). Social connection and sense of purpose also appear to matter. Chronic psychological stress is a modifiable factor that accelerates biological aging.

What we don't know

The dose-response relationship for different stress-reduction practices. Which clock types are most responsive. Whether the effects are independent of improved sleep and exercise, which often co-occur with stress reduction.

Key findings

Some randomized trials show epigenetic age reduction with meditation
Telomere lengthening observed in stress-reduction interventions
Inflammatory markers improve with chronic stress management
Effect sizes tend to be modest; studies are often small

Smoking Cessation

STRONG

Quitting smoking is one of the single most impactful changes for reducing biological age acceleration. The effects are visible across nearly every clock type.

Mechanism

Smoking directly accelerates DNA methylation aging, increases mortality-linked markers captured by GrimAge, and drives inflammation and glycan profile deterioration. Many of these changes are at least partially reversible after cessation.

Clock responsiveness

GrimAge was specifically designed to capture smoking-driven mortality risk. Quitting smoking partially reverses DNA methylation changes at smoking-associated sites. Inflammatory and glycomic markers begin improving within months of cessation.

In practice

Complete cessation is far more effective than reduction. Partial reversal of epigenetic damage occurs over years. Benefits to inflammatory markers begin within weeks.

What we don't know

How completely epigenetic smoking signatures reverse over time. Whether long-term former smokers ever fully normalize their biological age clocks. How smoking cessation interacts with other interventions.

Key findings

GrimAge directly incorporates smoking-related methylation signals
Cessation partially reverses smoking-associated methylation changes
Inflammatory markers improve rapidly after quitting
Some epigenetic signatures may persist for years after quitting

Diet Quality & Caloric Management

STRONG

Mediterranean-style diets and moderate caloric restriction show consistent effects on biological aging markers across multiple studies.

Mechanism

Anti-inflammatory foods reduce inflammatory signaling, improve metabolic markers, and shift glycan profiles (sugar molecules on proteins that change with aging). These dietary patterns also influence DNA methylation at aging-associated sites.

Clock responsiveness

The CALERIE trial showed that caloric restriction slowed DunedinPACE. GlycanAge is highly responsive to dietary changes. Phenotypic clocks improve as metabolic biomarkers normalize.

In practice

Emphasize whole foods, vegetables, healthy fats, and lean protein. Avoid ultra-processed foods. Moderate caloric restriction (10–15%) without malnutrition. Time-restricted eating shows early promise but needs more evidence.

What we don't know

Whether certain dietary patterns are better suited to certain clock types. Whether caloric restriction benefits are sustainable long-term. How much individual genetic variation affects dietary response.

Key findings

CALERIE trial: caloric restriction slowed DunedinPACE
Mediterranean diet linked to lower epigenetic age acceleration
GlycanAge responds to dietary changes within months
Anti-inflammatory diets improve phenotypic biomarkers

Exercise (4-Pillar Approach)

STRONG

The single most consistently supported intervention for slowing biological aging. The evidence points to four distinct types of exercise — each targeting different aspects of how the body ages.

Mechanism

Different exercise modalities target different aging pathways. Aerobic base training improves mitochondrial function and cardiovascular health. Strength training preserves muscle mass and metabolic rate, both of which decline with age. Balance and mobility work maintains neuromuscular function and reduces fall risk. High-intensity intervals improve VO2max — a strong independent predictor of longevity. Together, these four pillars shift DNA methylation patterns, reduce chronic inflammation, and improve insulin sensitivity.

Clock responsiveness

Multiple randomized trials show reduced epigenetic age acceleration with sustained exercise. DunedinPACE, which measures the current rate of aging, responds to structured programs combining aerobic and resistance training. Phenotypic clocks improve as cardiovascular, metabolic, and inflammatory biomarkers normalize.

In practice

A complete exercise program covers four pillars. Aerobic base: 150–300 minutes per week of Zone 2 cardio (60–70% max heart rate) — walking, jogging, or cycling. Strength: 2–3 sessions per week of full-body compound lifts with progressive overload. Balance and mobility: 15 minutes, three times per week, to preserve neuromuscular coordination. VO2max intervals: 1–2 sessions per week of 4×4-minute efforts at 90–95% max heart rate with active recovery between sets. Consistency across all four pillars matters more than maximizing any one.

What we don't know

The optimal balance between the four exercise types for maximum clock response. Whether exercise-driven clock changes reflect genuine biological rejuvenation or simply healthier biomarker levels. How durable the effects are if you stop exercising. Whether the optimal mix changes with age.

Key findings

Epigenetic age deceleration shown in multiple randomized trials
VO2max is one of the strongest independent predictors of longevity
Strength training preserves muscle mass and metabolic function with age
Balance and mobility training reduces fall risk — a major cause of disability in older adults

Sleep Optimization

STRONG

Consistent, quality sleep is linked to slower biological aging across multiple clock types. Disrupted sleep consistently accelerates aging markers.

Mechanism

Sleep supports DNA repair, immune regulation, hormone balance, and the resolution of inflammation. Chronic sleep disruption accelerates epigenetic aging and shifts immune and inflammatory profiles in ways that aging clocks detect.

Clock responsiveness

Sleep deprivation is associated with accelerated epigenetic clocks in observational studies. Inflammatory markers (captured by glycomic and immune clocks) worsen with poor sleep. Phenotypic biomarkers improve when sleep is restored.

In practice

Seven to nine hours for most adults. Consistent sleep and wake times matter. Address sleep disorders like apnea. Blue light management, cooler room temperatures, and stress reduction all support sleep quality.

What we don't know

Whether improving sleep can reverse accumulated epigenetic damage. The optimal sleep duration at different ages. How much of the clock sensitivity to sleep disruption is temporary versus lasting.

Key findings

Sleep disruption linked to accelerated epigenetic aging
Inflammatory markers worsen with chronic poor sleep
Short-term sleep loss may temporarily shift clock readings
Sleep quality correlates with biological age across populations

Targeted Therapeutics

Drugs and compounds under investigation as potential aging interventions. Promising in research, but not yet proven for healthy humans.

NAD+ Precursors (NMN, NR)

EMERGING

NMN and NR are supplements designed to boost levels of NAD+, a molecule essential for cellular energy and repair that declines with age. The science is mechanistically plausible but clinical evidence for aging clock effects is thin.

Mechanism

NAD+ is a coenzyme required for DNA repair, mitochondrial energy production, and the activity of sirtuin proteins involved in aging regulation. Supplementing its precursors (NMN or NR) can raise NAD+ levels, but whether this translates to slower aging is unproven.

Clock responsiveness

Limited direct biological age clock data. Some small studies show biomarker improvements. No large randomized trials have demonstrated clock reversal. The mechanistic logic is sound, but clinical translation remains uncertain.

In practice

Available as supplements. Typical doses range from 250–1000 mg daily. Generally well-tolerated. Quality and purity vary widely between brands. Regulatory status varies by country (NMN was briefly pulled from US supplement markets).

What we don't know

Whether raising NAD+ levels actually slows biological aging clocks. The optimal dose and form (NMN versus NR). Long-term safety data. Whether benefits extend beyond biomarker changes to meaningful health outcomes.

Key findings

NAD+ decline with age is well-established
Small human studies confirm that supplements raise NAD+ levels
Biological age clock effects not yet shown in randomized trials
Strong mechanistic rationale but clinical translation unclear

Metformin

PROMISING

A widely prescribed diabetes drug now being studied as a potential aging intervention. Large epidemiological datasets suggest reduced age-related disease in users, but the first rigorous trial in healthy adults is still underway.

Mechanism

Metformin activates a cellular energy sensor (AMPK), reduces inflammatory signaling, improves insulin sensitivity, and may influence DNA methylation patterns through its metabolic effects. These pathways overlap with those that aging clocks measure.

Clock responsiveness

Direct clock data in healthy humans is limited. The TAME trial (Targeting Aging with Metformin) will be the first large randomized trial measuring aging endpoints in non-diabetics. Some observational data suggest lower epigenetic age in users.

In practice

Prescription medication. Typically 500–1500 mg daily. Gastrointestinal side effects are common initially. Off-label use for longevity is widespread but not evidence-based for non-diabetics yet.

What we don't know

Whether metformin benefits healthy non-diabetics. TAME trial results are pending. Whether it truly slows biological aging clocks or just improves the metabolic markers they track. It may also blunt some exercise benefits when used concurrently.

Key findings

TAME trial (ongoing): first large aging-endpoint trial in non-diabetics
Diabetic metformin users may have lower mortality than non-diabetic controls
May reduce some exercise-related benefits when used together
Direct epigenetic clock evidence in healthy humans is limited

Senolytics (Dasatinib + Quercetin, Fisetin)

EMERGING

Drugs designed to selectively clear out senescent cells — damaged cells that stop dividing but don’t die, instead releasing inflammatory signals that accelerate aging in surrounding tissue.

Mechanism

Senolytics target the survival mechanisms that keep senescent cells alive, enabling their clearance. Removing these cells reduces their inflammatory secretions (known as SASP), a major driver of chronic low-grade inflammation and tissue dysfunction in aging.

Clock responsiveness

Animal studies show biological age reversal with senolytic treatment. Human pilot studies (using dasatinib + quercetin in pulmonary fibrosis and kidney disease) show promise. No large-scale clock studies in healthy humans yet.

In practice

Dasatinib is a prescription cancer drug. Quercetin and fisetin are available as supplements. Protocols typically use intermittent dosing (a few days per month) rather than daily use. Safety for chronic use in healthy people is not established.

What we don't know

Whether clearing senescent cells actually reverses biological age clocks in humans. The optimal timing, dosing, and who benefits most. The long-term effects of periodically eliminating senescent cells.

Key findings

Animal studies: biological age reversal and healthspan extension
Human pilot studies show feasibility and some biomarker improvements
Intermittent dosing may be sufficient (a few days per month)
Large-scale human clock studies not yet completed

Rapamycin / mTOR Inhibitors

PROMISING

The most robust lifespan-extending drug in animal studies. Human evidence in healthy older adults remains thin — the first published RCT pairing weekly sirolimus with a structured exercise program (RAPA-EX-01; Stanfield, Kaeberlein et al., 2026) found no benefit on its primary functional endpoint and no signal on methylation clocks over 13 weeks.

Mechanism

Rapamycin inhibits a growth-signalling pathway called mTOR, which enhances cellular recycling (autophagy), reduces the accumulation of damaged cells, and improves how cells maintain their proteins — processes directly tied to aging biology. The clinical question is whether intermittent low-dose protocols translate the animal lifespan effect into measurable human benefit without offsetting costs to muscle, immunity, or recovery.

Clock responsiveness

Animal studies show epigenetic age reversal with rapamycin treatment. In humans, the first randomized trial to measure methylation clocks under weekly rapamycin alongside structured exercise (RAPA-EX-01, n=40, 13 weeks) found no significant difference vs placebo. The trial was small and short; it does not rule out effects at longer horizons or other dosing schedules.

In practice

Prescription immunosuppressant with a significant side-effect profile at standard doses. Longevity protocols use intermittent low doses (e.g., weekly) to minimize immune suppression. Not approved for aging by any regulator. The most-discussed consumer protocol — weekly dosing alongside structured exercise — has now been tested in a published RCT and did not improve outcomes over exercise alone.

What we don't know

Whether any dosing schedule produces durable human longevity benefit. Whether the RAPA-EX-01 result (rapamycin + exercise underperforming exercise + placebo on lower-extremity function) replicates in larger and longer studies. Whether rapamycin transiently impairs the muscular and recovery response to training in older adults. Whether longer durations or different dosing windows would change the methylation-clock signal.

Key findings

Extends lifespan in mice, flies, worms, and yeast — the strongest animal-model evidence of any candidate longevity drug
In the first published RCT pairing weekly sirolimus (6 mg) with a 13-week structured exercise program in older adults (RAPA-EX-01; Stanfield, Kaeberlein et al., 2026; n=40, ages 65–85), the placebo + exercise group performed significantly better on the primary 30-second chair-stand endpoint (per-protocol p=0.007, Cohen's d=−0.90)
Methylation clocks, grip strength, 6-minute walk, and CRP showed no significant differences between arms in that trial
Authors are well-known rapamycin advocates — the direction of the finding is unlikely to reflect anti-rapamycin bias
Side-effect profile and lack of human longevity outcome data continue to limit use outside clinical trials

Emerging Technologies

Experimental approaches in early research stages. Exciting biology, but far from clinical use.

Partial Cellular Reprogramming

EMERGING

An experimental technique that uses a set of proteins (Yamanaka factors) to partially reset a cell’s epigenetic marks to a more youthful state — without fully reverting it to a stem cell. Remarkable in mice; far from human use.

Mechanism

Brief exposure to four proteins (Oct4, Sox2, Klf4, c-Myc) can erase some of the epigenetic changes associated with aging while preserving a cell’s identity and function. In mice, this has rejuvenated tissues and extended lifespan.

Clock responsiveness

Demonstrates clear epigenetic age reversal in mouse studies and in lab-grown human cells. Several well-funded companies (Altos Labs, Retro Biosciences) are working on translating this to humans.

In practice

Entirely experimental. Not available outside research laboratories. Major safety concerns, including cancer risk (one of the four proteins, c-Myc, is a known cancer driver). Delivery, dosing, and tissue targeting are unsolved problems.

What we don't know

Whether partial reprogramming is safe in humans. The optimal combination and delivery method for the reprogramming factors. Whether epigenetic age reversal actually translates to functional rejuvenation. How long until human therapies might exist.

Key findings

Mouse studies show tissue rejuvenation and lifespan extension
Epigenetic age reversal demonstrated in lab-grown human cells
Major biotech investment (Altos Labs, Retro Biosciences)
Safety and delivery remain fundamental unsolved challenges

Hyperbaric Oxygen Therapy (HBOT)

EMERGING

Breathing pure oxygen at elevated pressure in a specialized chamber. One small trial reported telomere lengthening and reduced senescent cells, but the results have not been independently replicated.

Mechanism

Cycles of high and normal oxygen levels may trigger a protective stress response, mobilize stem cells, reduce senescent cell burden, and modulate immune function. The theory is that intermittent oxygen stress prompts cellular repair mechanisms.

Clock responsiveness

One small Israeli study (35 participants) reported telomere lengthening and senescent cell reduction after 60 sessions. Epigenetic clock data is very limited. These results have not been independently replicated at scale.

In practice

Requires specialized hyperbaric chambers. Expensive: $100–250 per session, with study protocols using 60 or more sessions. HBOT has established medical uses (wound healing, decompression sickness) but longevity claims are far ahead of the evidence.

What we don't know

Whether the small trial results will replicate in larger studies. The optimal protocol (pressure, duration, frequency). Whether telomere changes translate to meaningful biological age reversal. Long-term safety of repeated protocols.

Key findings

One small trial (35 participants): telomere lengthening, fewer senescent cells
Results have not been independently replicated
Established medical therapy being repurposed for longevity
High cost and limited access are significant barriers

Young Plasma / Parabiosis Factors

EMERGING

Research into specific molecules in young blood that may rejuvenate aged tissues. Inspired by experiments where old and young mice share a circulatory system, leading to tissue rejuvenation in the older animal.

Mechanism

Young blood contains signaling molecules that may rejuvenate aged tissues. When old and young mice are surgically connected (parabiosis), the older mouse shows rejuvenation of muscle, brain, and liver. Researchers are now trying to identify the specific factors responsible — and whether simply diluting old plasma helps too.

Clock responsiveness

Animal parabiosis experiments show epigenetic age changes in the older partner. Human plasma exchange pilot studies exist but are very small. Direct biological age clock data in humans is extremely limited.

In practice

Not available as a validated therapy. Plasma exchange is a medical procedure with its own risks. The FDA has warned against unproven young plasma treatments (like those previously marketed by Ambrosia). This is an active research area with no consumer-ready product.

What we don't know

Which specific molecules drive the rejuvenation effect. Whether plasma exchange or isolated factors would be more effective. Safety of repeated plasma manipulation. Whether any of this works in humans the way it works in mice.

Key findings

Parabiosis experiments show tissue rejuvenation in old mice
Specific candidate factors identified but results are debated
Diluting old plasma may matter as much as adding young factors
FDA has warned against unproven young plasma treatments